Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 in combination with anti-tumor agents in KRAS G12D mutant advanced solid tumors
NCT06520488Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Aug 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in solid tumor (advanced stage), sponsored by Hengrui. Started Aug 2024; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06520488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520488.